HTFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Heartflow Inc (HTFL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong growth potential, supported by a 40.51% YoY revenue increase and positive analyst sentiment. Despite the lack of recent trading signals and neutral insider/hedge fund activity, its innovative AI-based solutions and a projected 20% growth rate over the next three years make it a compelling long-term investment opportunity.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 59.037, showing no overbought or oversold conditions. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance is at 25.056, with support at 23.406. The pre-market price of 25.05 is testing the first resistance level, suggesting potential upward movement if it breaks through.
Wells Fargo initiated coverage with an Overweight rating and a $38 price target, citing strong growth potential and a first-mover advantage in AI-based coronary artery disease diagnosis.
The company reported a 40.51% YoY revenue growth in Q3 2025, with a gross margin of 76.53%.
Positive sentiment around its FFRCT and plaque analysis technology, which is expected to drive 20% growth over the next three years.
Lack of recent news or significant insider/hedge fund trading activity.
Bearish moving averages indicate potential short-term weakness.
No recent congress trading data or influential figure activity.
In Q3 2025, Heartflow's revenue increased by 40.51% YoY to $46.28 million. Net income improved significantly, up 165.70% YoY, though still negative at -$50.86 million. EPS improved by 333.33% YoY to -1.04, and gross margin increased slightly to 76.53%. These metrics indicate strong growth trends despite ongoing losses.
Wells Fargo initiated coverage with an Overweight rating and a $38 price target, highlighting the company's first-mover advantage in AI-based coronary artery disease diagnosis and management. Analysts expect a 20% growth rate over the next three years, driven by its innovative FFRCT and plaque analysis technology.
